New triple combo targets tough lung cancer liver spread
NCT ID NCT07258147
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding radiation to immunotherapy and chemotherapy can help people with advanced small-cell lung cancer that has spread to the liver. It includes 30 adults aged 18-75 whose cancer did not respond to or stopped responding to prior treatments. The goal is to see if the combination shrinks tumors and delays disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood, urine, and stool may hold the key to predicting a serious side effect of lung cancer treatment
- Can a Two-Drug attack shrink tough lung cancers?
- Can a smartphone app ease the burden of advanced lung cancer?
- Cholesterol-Lowering drug may boost lung cancer immunotherapy
- Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
- New combo shows promise for tough lung cancer